This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.

EuropaBio notes the adoption by the European Parliament of the report on EU options for improving patient access to medicines on 2 March 2017, in Brussels.

European Commission Initiative Improves Information for Patients on Biosimilar Medicines.